Topical Cyclosporine and Disease Progression
Information source: Innovative Medical
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Disease Progression; Disease Severity; Staining; Schirmers; OSDI
Intervention: Restasis (Drug); Endura (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Innovative Medical Official(s) and/or principal investigator(s):
Sanjay Rao, Principal Investigator, Affiliation: Lakeside Eye Clinic
Overall contact:
Melissa Earl, Phone: 951-786-0403, Email: m.earl@imedsonline.com
Summary
The purpose of this study is to evaluate the effect Restasis has in regards to disease
progression.
Clinical Details
Official title: Topical Cyclosporine and Disease Progression
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Primary outcome: Disease Severity
Secondary outcome: Staining
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Mild to Moderate dry eye symptoms
Exclusion Criteria:
- Current use of Restasis
Locations and Contacts
Melissa Earl, Phone: 951-786-0403, Email: m.earl@imedsonline.com
Lakeside Eye Clinic, Chicago, Illinois 60641, United States; Recruiting
Sanjay Rao, MD, Phone: 312-641-5501, Email: sanjayrao@pol.net
Additional Information
Starting date: December 2007
Ending date: December 2008
Last updated: December 4, 2007
|
